Vivian Shi, MD, FAAD, reviews recent phase 3 data on bimekizumab, a biologic therapy for patients with hidradenitis suppurativa.
Video content above is prompted by the following:
Real-World Data Support Dual Benefit of Biologic Therapy for Hidradenitis Suppurativa
September 27th 2025The study confirms that biologics are highly effective in real-world HS management, and highlights the need for a comprehensive treatment strategy considering both skin symptoms and systemic health.
Read More